Gut microbiota and inflammatory monocytes in colorectal cancer
Gut microbiota and inflammatory monocytes in colorectal cancer
批准号:
8607163
负责人:
Wendy S. Garrett
金额:
$32.51万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-18 至 2016-02-29
关键词:
AdenocarcinomaAgeAnti-Inflammatory AgentsAnti-inflammatoryAreaAutomobile DrivingBacteriaBiometryCancer BiologyCancer EtiologyCell ProliferationCellsCellular biologyCessation of lifeChronicColitisCollaborationsColonColon CarcinomaColorectal CancerCommunitiesComputational BiologyComputing MethodologiesDana-Farber Cancer InstituteDataData SetDendritic CellsDevelopmentDigestive System DisordersDiseaseDysplasiaEnvironmentEvolutionGerm-FreeGrantHumanImmuneImmune responseImmunityImmunologyIncidenceInflammationInflammatoryInflammatory Bowel DiseasesInflammatory ResponseInstitutesIntestinal CancerIntestinesLightMalignant NeoplasmsMicrobeMicrobiologyModelingMolecularMucosal Immune ResponsesMucous MembraneMusMyelogenousMyeloid CellsNatural ImmunityNeoplasmsPatientsPenetrancePopulationPublishingResearchResearch PersonnelRisk FactorsRoleShapesSignal PathwayStagingTechniquesTechnologyTherapeuticUlcerative ColitisUniversitiesadaptive immunitycancer cellcancer therapycarcinogenesisfunctional genomicsgenome sequencinggut microbiotahigh riskhuman diseaseinsightmacrophagemedical schoolsmembermicrobial communitymicrobial hostmicroorganism interactionmigrationmonocytemouse modelneoplasticpreventpublic health relevanceresponsestemtooltranscriptomicstumortumor microenvironmenttumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the second leading cause of cancer-related death and the third most common cancer in the US. Inflammation is a key contributor to carcinogenesis, and there is an increased incidence of cancer in patients with chronic inflammatory diseases. Inflammation in the tumor microenvironment can enhance cancer cell proliferation, survival, and migration. A chronically inflamed colonic mucosa is pro- neoplastic; and ulcerative colitis (UC) is one of the highest risk factors for the development of CRC. Recent data suggest that immune responses to commensal gut bacteria may influence the development of CRC and colitis-associated colorectal cancer (caCRC). However, how the gut microbiota shapes mucosal immune responses leading to chronic inflammation and CRC is not well understood. Important questions include: (1) what are the features of the gut microbiota that elicit chronic inflammatory responses that drive caCRC and (2) how do mucosal innate immune subsets function in the evolving tumor microenvironment. This proposal builds on our recent studies of a spontaneous mouse model of UC and caCRC that is driven genetically by T-bet deficiency in the absence of adaptive immunity, and stems from our preliminary data on the microbial communities that instigate colitis. Our specific aims are to: 1) define the role of fecal microbial community members in initiating the innate immune driven inflammatory cascades that drive caCRC; 2) characterize monocyte populations and their recruitment, function, and response to the intestinal microbiota across the colitis r dysplasia r adenocarcinoma transition; and 3) perform a functional genomic analysis of fecal microbial communities across the colitis r dysplasia r adenocarcinoma transition. We employ cell biology, immunology, and microbiology techniques and sequencing technology as experimental tools, in conjunction, with computational methodology capable of integrating these diverse data sets. By analyzing the function of intestinal microbial communities and innate immune subsets in driving pro-neoplastic inflammation, this proposal will advance basic understanding of the contribution of host-microbial interactions to the evolution of a tumor microenvironment. Since we utilize a mouse model that is reminiscent of UC and recapitulates key features of human IBD-associated CRC, we anticipate that our data will be applicable for human disease and for the development of anti-inflammatory host and/or microbe directed therapeutics that will prevent the development and progression of cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Designer Probiotics for the treatment of intestinal infection and inflammation
-
批准号:9356497
-
项目类别:
-
资助金额:$74.41万
-
财政年份:2016
-
负责人:Wendy S. Garrett
-
依托单位:
Designer Probiotics for the treatment of intestinal infection and inflammation
-
批准号:9769017
-
项目类别:
-
资助金额:$73.51万
-
财政年份:2016
-
负责人:Wendy S. Garrett
-
依托单位:
Designer Probiotics for the treatment of intestinal infection and inflammation
-
批准号:10004029
-
项目类别:
-
资助金额:$73.34万
-
财政年份:2016
-
负责人:Wendy S. Garrett
-
依托单位:
Gut microbiota and inflammatory monocytes in colorectal cancer
-
批准号:8816042
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
-
批准号:10665786
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
-
批准号:9977924
-
项目类别:
-
资助金额:$34.67万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
-
批准号:10207518
-
项目类别:
-
资助金额:$34.67万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
-
批准号:9307232
-
项目类别:
-
资助金额:$34.67万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Gut microbiota and inflammatory monocytes in colorectal cancer
-
批准号:8444653
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Gut microbiota and inflammatory monocytes in colorectal cancer
-
批准号:8021447
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Gut microbiota and inflammatory monocytes in colorectal cancer
-
批准号:8245012
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2011
-
负责人:Wendy S. Garrett
-
依托单位:
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis
-
批准号:8417760
-
项目类别:
-
资助金额:$12.52万
-
财政年份:2009
-
负责人:Wendy S. Garrett
-
依托单位:
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis
-
批准号:7661987
-
项目类别:
-
资助金额:$9.93万
-
财政年份:2009
-
负责人:Wendy S. Garrett
-
依托单位:
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis
-
批准号:8223173
-
项目类别:
-
资助金额:$12.52万
-
财政年份:2009
-
负责人:Wendy S. Garrett
-
依托单位:
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis
-
批准号:8013740
-
项目类别:
-
资助金额:$3.08万
-
财政年份:2009
-
负责人:Wendy S. Garrett
-
依托单位:
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis
-
批准号:8038457
-
项目类别:
-
资助金额:$12.52万
-
财政年份:2009
-
负责人:Wendy S. Garrett
-
依托单位:
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis
-
批准号:8033644
-
项目类别:
-
资助金额:$3.39万
-
财政年份:2009
-
负责人:Wendy S. Garrett
-
依托单位:
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis
-
批准号:7775090
-
项目类别:
-
资助金额:$12.51万
-
财政年份:2009
-
负责人:Wendy S. Garrett
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: